Aktis Oncology

US · AKTS #3249 by market cap Listed 2026

17.53 -0.47 -2.64%

Live - 5344 symbols - heartbeat 116s ago · 2026-10-08 09:58

Pre-market 17.87 -0.72%

After-hours 18.00 0.00%

Market cap: 974.75M
P/E (TTM): -12.81
P/B: 2.01
EPS: -1.15
Div yield: 0.00%
52W pos: 14%

Reader sentiment Are you bullish or bearish on AKTS?

Anonymous reader poll. Unscientific, not investment advice.

About Aktis Oncology

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.

Founded: 2020
CEO: Mr. Matthew Roden, PhD
Employees: 75
Headquarters: Boston, Massachusetts, United States of America
Fiscal year end: 12-31
Website: aktisoncology.com

Company profile

Exchange: US
Symbol: AKTS
Market-cap rank: #3249
Listing date: 2026-01-09
Market cap: 974.75M
Float cap: 493.40M
Shares out: 55.62M
Float shares: 28.15M

Sectors & themes

Biotechnology IPOs

Browse all sectors & themes

Quote time 2026-10-08 09:58:12 · For reference only, not investment advice and not tailored to your situation.